Microvast Holdings announces departure of chief financial officer
On Monday, H.C. Wainwright reaffirmed a Buy rating on Benitec BioPharma (NASDAQ:BNTC) shares, maintaining a $28.00 price target. The stock has shown remarkable momentum, delivering a 225% return over the past year and currently trading near its 52-week high of $16.90. The firm’s analysts highlighted the biotechnology company’s ongoing progress in its Phase 1b/2a clinical trial for BB-301, an investigational treatment for oculopharyngeal muscular dystrophy (OPMD). As the trial advances, Benitec is preparing to administer the low dose of BB-301 to the sixth participant in the next quarter. According to InvestingPro data, analyst consensus remains strongly bullish, with price targets ranging from $17 to $35.
The company has plans to escalate the trial later this year by commencing treatment of a second cohort with an increased dose of BB-301. This step is part of Benitec’s strategy to evaluate the efficacy and safety of the drug at different dosage levels. The firm’s analysts have expressed confidence in the potential of BB-301, as reflected in their reiterated price target and rating. InvestingPro analysis shows the company maintains strong financial health with a current ratio of 25.48 and more cash than debt on its balance sheet, providing runway for its clinical development programs.
Benitec BioPharma’s focus on OPMD, a rare and currently untreatable genetic disorder that affects muscles in the eyes and throat, represents an area of high unmet medical need. BB-301 is being developed as a gene therapy to provide long-term and sustained expression of the therapeutic protein needed to improve muscle function in patients with OPMD.
The continuation of the Phase 1b/2a trial and the upcoming treatment of new subjects are significant steps for Benitec as it seeks to establish BB-301’s clinical profile. The company’s steady progress in its clinical program underpins H.C. Wainwright’s positive outlook on the stock.
Investors and stakeholders in Benitec BioPharma will be watching closely as the company proceeds with its clinical trial and aims to deliver on the promise of BB-301 for patients with OPMD. The reaffirmed Buy rating and price target from H.C. Wainwright signal a steady vote of confidence in the company’s trajectory and potential for growth.
In other recent news, Benitec Biopharma Inc. has reported promising interim results from its Phase 1b/2a study of the investigational gene therapy BB-301 for treating Oculopharyngeal Muscular Dystrophy (OPMD). The study demonstrated sustained improvements in swallowing function among subjects, with no severe adverse events reported. This development comes as Benitec prepares to present further clinical updates at the Muscular Dystrophy Association Clinical and Scientific Conference. Analysts from JMP have maintained a Market Outperform rating for Benitec, with a price target of $18, reflecting confidence in the company’s innovative "silence and replace" strategy. Similarly, H.C. Wainwright analysts have reiterated their Buy rating and a $28 price target, citing the positive progress of the BB-301 trial. The trial’s advancements have been marked by the successful dosing of additional patients, furthering the potential of Benitec’s therapeutic approach. Citizens JMP also expressed optimism, maintaining their Market Outperform rating and $18 price target, anticipating significant gains from the forthcoming data presentation. Investors and stakeholders are closely monitoring Benitec’s progress as it continues to make strides in its clinical trials and strategic initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.